Evidence map›Paper›PMID 28508122›Full record

ArticlePharmaceutical research2017

A Trivalent Enzymatic System for Uricolytic Therapy of HPRT Deficiency and Lesch-Nyhan Disease.

Luca Ronda, Marialaura Marchetti, Riccardo Piano, Anastasia Liuzzi, Romina Corsini, Riccardo Percudani, Stefano Bettati

Open access · hybridAbstract read
In one paragraph

Article in Pharmaceutical research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 16 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Luca RondaDepartment of Medicine and Surgery,, University of Parma, Parco Area delle Scienze 23/A, 43124, Parma, Italy.
Marialaura MarchettiDepartment of Chemistry, Life Sciences, and Environmental Sustainability, University of Parma,, Parco Area delle Scienze 23/A, 43124, Parma, Italy.
Riccardo PianoDepartment of Medicine and Surgery,, University of Parma, Parco Area delle Scienze 23/A, 43124, Parma, Italy.
Anastasia LiuzziDepartment of Chemistry, Life Sciences, and Environmental Sustainability, University of Parma,, Parco Area delle Scienze 23/A, 43124, Parma, Italy.
Romina CorsiniDepartment of Chemistry, Life Sciences, and Environmental Sustainability, University of Parma,, Parco Area delle Scienze 23/A, 43124, Parma, Italy.
Riccardo PercudaniDepartment of Chemistry, Life Sciences, and Environmental Sustainability, University of Parma,, Parco Area delle Scienze 23/A, 43124, Parma, Italy. riccardo.percudani@unipr.it.ORCID http://orcid.org/0000-0001-8452-1062
Stefano BettatiDepartment of Medicine and Surgery,, University of Parma, Parco Area delle Scienze 23/A, 43124, Parma, Italy. stefano.bettati@unipr.it.
University of Parma · IT

Funding

Telethon GGP13149
6 · The paper itself

Abstract

purposeBecause of the evolutionary loss of the uricolytic pathway, humans accumulate poorly soluble urate as the final product of purine catabolism. Restoration of uricolysis through enzyme therapy is a promising treatment for severe hyperuricemia caused by deficiency of hypoxanthine-guanine phosphoribosyltransferase (HPRT). To this end, we studied the effect of PEG conjugation on the activity and stability of the enzymatic complement required for conversion of urate into the more soluble (S)-allantoin.

methodsWe produced in recombinant form three zebrafish enzymes required in the uricolytic pathway. We carried out a systematic study of the effect of PEGylation on the function and stability of the three enzymes by varying PEG length, chemistry and degree of conjugation. We assayed in vitro the uricolytic activity of the PEGylated enzymatic triad.

resultsWe defined conditions that allow PEGylated enzymes to retain native-like enzymatic activity even after lyophilization or prolonged storage. A combination of the three enzymes in an appropriate ratio allowed efficient conversion of urate to (S)-allantoin with no accumulation of intermediate metabolites.

conclusionsPharmaceutical restoration of the uricolytic pathway is a viable approach for the treatment of severe hyperuricemia.

Indexed as

AllantoinAmidohydrolasesAnimalsCarboxy-LyasesEnzyme TherapyHumansHyperuricemiaHypoxanthine PhosphoribosyltransferaseLesch-Nyhan SyndromeMolecular WeightPolyethylene GlycolsRecombinant ProteinsSolubilityStereoisomerismUrate OxidaseUric AcidAllantoinAmidohydrolasesCarboxy-Lyaseshydroxyisourate hydrolaseHypoxanthine PhosphoribosyltransferasePolyethylene GlycolsRecombinant ProteinsUrate OxidaseUric AcidUricosuric Agentsenzyme therapygouthyperuricemiaLesch-Nyhan diseasepolyethylene glycolpurine degradation

Identifiers

PMID28508122
PMCPMC5445154
OpenAlexW2614191860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.